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Background
Approximately 70% of newly diagnosed breast cancers 
express detectable levels of estrogen receptor alpha 
(ERα). Patients with these tumors generally receive an 
endocrine-based intervention, usually in the form of an 
aromatase inhibitor or antiestrogen. While these inter-
ven  tions are associated with a signiﬁ   cant increase in 
overall survival [1], many ERα-positive breast cancers 
recur.
Breast cancer cells often respond to endocrine thera-
pies by altering the expression of a subset of estrogen-
responsive and nonresponsive genes and inducing 
autophagy [2-7]. Autophagy is a lysosomal self-digestion 
pathway, where selected subcellular components are ﬁ  rst 
segregated into double membrane-bound structures 
called autophagosomes [8]. Subsequent fusion with lyso-
somes forms autolysosomes, which enables the materials 
sequestered therein to be digested by lysosomal hydro-
lases. Th   ree primary forms of autophagy have been des-
cribed: macroautophagy, microautophagy, and chaperone-
mediated autophagy. Th  e comments in this viewpoint 
relate primarily to macroautophagy.
Autophagy can be prodeath or prosurvival and reﬂ  ects 
an attempt by stressed cells to eliminate damaged or 
other organelles and recover the energy stored in their 
macromolecules to restore metabolic homeostasis. 
Autophagy can result from activation of the unfolded 
protein response (UPR) [9] in response to the metabolic 
stress of endocrine therapies [4]. In endocrine manipu-
lated cells, prosurvival autophagy signaling is driven at 
least partly by UPR activation of the uncon  ven  tional 
splicing of the estrogen-responsive XBP1 mRNA [3,10] 
and, downstream, increased expression of BCL2 family 
members including BCL2 and BCLW (BCL2L2) [11]. 
Prodeath signaling can involve induction of a caspase-
dependent apoptotic cell death (programmed cell death 1) 
[12] when there is adequate energy, and an autophagy-
associated necrotic cell death that is probably energy 
independent [11]. An autophagic cell death, often 
referred to as programmed cell death 2, also occurs. Th  e 
extent of autophagy induced in response to stress may be 
controlled by the respective abilities of BCL2 and BCLW, 
and perhaps other BCL2 family members, to bind and 
sequester BECN1 [11], a key inducer of autophagy [8]. 
Regulation of the mammalian target of rapamycin 
(mTOR) by AKT also aﬀ  ects the induction of autophagy, 
and AKT is associated with UPR signaling [9].
An individual cell’s fate can be determined by the 
extent and duration of autophagy. Prolonged exposure to 
a high level of autophagy can leave the cell with insuf-
ﬁ  cient mitochondria and/or other organelles to survive 
(prodeath autophagy). Adequate recovery of energy by 
autophagy, with a suﬃ   cient remaining subcellular infra-
structure, can allow the cell to survive (prosurvival 
autophagy) [13]. In the face of endocrine therapies, this 
survival is manifest as drug resistance.
The article
A recent study by Gonzalez-Malerva and colleagues used 
gene expression microarray analysis, and a functional 
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human kinase cDNAs, to study resistance in a series of 
MCF-7 cells with diﬀ   ering tamoxifen responses [14]. 
Th  irty-one kinases were identiﬁ  ed that both enhanced 
cell proliferation in the presence of 4-hydroxytamoxifen 
and were validated in at least four of six independent 
experiments. ERBB2 and IGF1R were among those genes 
that scored at least twice in these experiments, were 
diﬀ  erentially regulated in the microarray dataset, and are 
known to aﬀ  ect endocrine responsiveness [2]. Among the 
genes identiﬁ  ed, the authors selected HSPB8 (heat shock 
22 kDa protein 8; E2-induced gene protein 1; α-crystallin 
C chain) for further evaluation because this gene gave 
one of the strongest responses in their primary assay, 
validated in ﬁ  ve out of six screens, and was present in 
their microarray signature. A role for HSBP8 in tamoxifen 
resistance has not previously been reported.
Subsequent analyses in vitro showed that HSBP8 
reduced the antiproliferative eﬀ  ects of 4-hydroxy  tamoxi-
fen and blocked its ability to induce autophagy. Th  e 
eﬀ   ects on autophagy were not mediated by chemical 
inhibi  tion of the autophagy regulator mTOR, although 
the mTOR pathway was aﬀ  ected as assessed by changes 
in p70S6kP and 4-EBP1P. HSBP8 similarly aﬀ  ected these 
two proteins but independently of mTOR. An association 
of HSPB8 (α-crystallin C chain) expression with a poor 
clinical outcome was described in one clinical gene 
expression dataset  [14], an association previously 
reported for the α-crystallin B chain protein [15]. Overall, 
the authors concluded that autophagy may be an 
important player in aﬀ  ecting tamoxifen sensitivity and 
noted that the mechanism of HSBP8 action requires 
further study.
Viewpoint
Activation of autophagy is clearly a key determinant of 
the nature of the response to antiestrogens in some 
breast cancer cells. In cells that are forced (and able) to 
activate an energy-dependent programmed cell death, it 
seems probable that autophagy provides both the energy 
and part of the cell destruction machinery. Th  ere are 
advantages to an orderly cell death that results in the 
release of at least partly digested cellular components, 
which may be less likely to induce the destructive inﬂ  am-
matory response associated with an apparently chaotic 
necrotic cell death. Adjacent cells in the micro  environ-
ment may be able to scavenge and more eﬃ   ciently use 
released macromolecules to support their own attempt to 
evade the shared metabolic stress. For endocrine 
therapies, the prolonged duration of autophagy – even 
when prodeath is not immediately lethal – may explain 
why cell death is generally slow in vitro and why complete 
pathological responses are infrequent even among highly 
responsive ERα-positive breast tumors. While the study 
by Gonzalez-Malerva and colleagues primarily addressed 
prodeath autophagy, a prosurvival autophagic adaptation 
to the nutrient deprivation present in poorly vascularized 
and/or endocrine-resistant tumors may explain the 
some  times decades-long dormancy associated with 
breast cancer development and recurrence.
Gonzalez-Malerva and colleagues clearly add HSBP8 to 
the list of genes associated with endocrine resistance and 
autophagy [14]. How HSBP8 inﬂ   uences autophagy is 
unclear but the mechanism does not seem to involve 
mTOR. Th  e researchers did not look in detail at other 
mechanisms such as those that aﬀ  ect BECN1 action, a 
pathway known to aﬀ  ect autophagy in endocrine res-
ponsive ness.  Th  e authors also implicate pathways inde-
pen  dent of HSBP8 in antiestrogen resistance. Whether 
HSBP8 will be validated as an independent prognostic or 
predictive marker is not clear, since this was not seen in 
the independent dataset [14]. Nonetheless, HSBP8 is an 
interesting and important new addition to our under-
standing of cannibalistic autophagy signaling in endo-
crine resistance.
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